🇺🇸 FDA
Patent

US 11236338

Antisense-induced exon2 inclusion in acid alpha-glucosidase

granted A61PA61P3/08A61P3/10

Quick answer

US patent 11236338 (Antisense-induced exon2 inclusion in acid alpha-glucosidase) held by Sarepta Therapeutics, Inc. expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sarepta Therapeutics, Inc.
Grant date
Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61P, A61P3/08, A61P3/10, A61P43/00